Correction: Exclusive destruction of mitotic spindles in human cancer cells

Leonid Visochek; Asher Castiel; Leonid Mittelman; Michael Elkin; Dikla Atias; Talia Golan; Shai Izraeli; Tamar Peretz; Malka Cohen-Armon

doi:10.18632/oncotarget.27499

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Exclusive destruction of mitotic spindles in human cancer cells

PDF | How to cite

Oncotarget. 2020; 11:1290-1291. https://doi.org/10.18632/oncotarget.27499

Metrics: PDF 1031 views | ?

Leonid Visochek¹, Asher Castiel², Leonid Mittelman³, Michael Elkin⁴, Dikla Atias², Talia Golan², Shai Izraeli^2,5, Tamar Peretz⁴ and Malka Cohen-Armon^1,6

¹ The Neufeld Cardiac Research Institute, Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
² Cancer Research Center, Sheba Medical Center, Ramat Gan 53621, Israel
³ The Imaging Unit, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
⁴ Sharett Oncology Institute, Hadassah Medical Center, Ein-Kerem, Jerusalem 91120, Israel
⁵ The Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
⁶ Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978, Israel

Published: April 07, 2020

This article has been corrected: There was an error during the assembly of the bottom panel of Figure 5B. Instead of displaying IP of α-tubulin by α-tubulin and NuMA IP by NuMA, NuMA IP by NuMA was displayed twice. The correct Figure 5B is shown below. There are no changes in the figure legend. The authors declare that this correction does not change the results and conclusions of the paper.

Original article: Oncotarget. 2017; 8:20813–20824. DOI: https://doi.org/10.18632/oncotarget.15343.

Figure 5: PJ34 inhibits NuMA and tankyrase1 polyADP-ribosylation in cancer cells. (B) The binding of tankyrase1 to γ-tubulin or NuMA was measured by co-immunoprecipitation. Their binding in MDA-MB-231 cells was not affected by treatment with PJ34 (20 μM, 27 h). The binding of tankyrase1 to kinesin HSET/kifC1 was impaired. Representative results of 3 experiments are displayed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27499

Publication Alerts

Corrections:

Correction: Exclusive destruction of mitotic spindles in human cancer cells